An astonishing breakthrough in gene therapy has offered new hope to thousands of families affected by Huntington’s disease in the UK. Researchers at University College London have announced that a new treatment, AMT-130, has slowed the progression of the disease by an unprecedented 75%. This development marks the first time a therapy has shown such a dramatic impact on the course of this fatal neurodegenerative disorder.
Huntington’s disease is caused by a mutation in the HTT gene. This mutation leads to the production of a toxic version of the huntingtin protein, which gradually destroys neurons in the brain. Symptoms typically appear in mid-adulthood and include movement disorders, cognitive decline, and emotional disturbances. Until now, treatments could only manage symptoms, not alter the disease’s trajectory.
The new gene therapy works by delivering custom DNA into brain cells using a harmless virus. This DNA instructs cells to produce microRNA molecules that silence the faulty gene. As a result, the production of the toxic protein is significantly reduced. The therapy is administered during brain surgery and is designed to be a one-time treatment.
In the gene therapy clinical trial, 29 patients received AMT-130, with 17 receiving a high dose. Over three years, those in the high-dose group showed 75% less disease progression compared to untreated individuals. This was measured using standard scales that assess motor, cognitive, and functional abilities. Researchers also observed a decline in biomarkers of neurodegeneration, further confirming the therapy’s effectiveness.
Dr. Ed Wild, a consultant neurologist at UCL, described the results as life-changing. He noted that some patients who were expected to need wheelchairs are still walking. One participant even returned to work after being medically retired. These outcomes suggest that the therapy could extend both lifespan and quality of life for patients.
Professor Sarah Tabrizi, who co-led the trial, expressed deep optimism. She said the results exceeded all expectations and could transform the treatment landscape for Huntington’s disease. The therapy’s impact was not only clinical but also emotional, offering families a future they never thought possible.
The trial’s sponsor, uniQure, plans to submit a Biologics License Application to the US FDA in early 2026. Approval in the UK and Europe is expected to follow. The therapy has already received Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations, which could accelerate its regulatory review.
While the results are preliminary and not yet peer-reviewed, the data have generated excitement across the medical community. Experts caution that more testing is needed to confirm long-term safety and efficacy. However, the early findings are promising and suggest that gene therapy could become a cornerstone in treating not only Huntington’s but also other neurodegenerative diseases.
The implications of this breakthrough extend beyond Huntington’s. Researchers believe that similar gene therapy approaches could be adapted to treat conditions like Parkinson’s and Alzheimer’s. By targeting the genetic roots of these diseases, scientists hope to develop treatments that go beyond symptom management.
In the UK, around 8,000 people live with Huntington’s disease, and many more are at risk due to its hereditary nature. Each child of an affected parent has a 50% chance of inheriting the mutation. For these families, the new therapy offers a glimmer of hope that was previously unimaginable.
The treatment’s delivery method, though complex, is manageable. Surgeons use MRI guidance to inject the therapy into specific brain regions. The procedure takes 12 to 18 hours but requires only one dose. Most side effects reported were related to the surgery and resolved without complications.
As the scientific community awaits peer-reviewed publication of the trial data, patients and families are already celebrating. The possibility of slowing or even halting the disease’s progression is a monumental shift. For decades, Huntington’s has been a diagnosis with no escape. Now, thanks to gene therapy, that narrative may be changing.
This breakthrough is not just a scientific achievement; it is a testament to the courage of patients who volunteered for the trial. Their bravery has paved the way for a future where Huntington’s disease is no longer a life sentence. With continued research and collaboration, the promise of gene therapy could soon become reality for thousands more.
About the Author
